- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04045600
Refinements of Functional Communication Training
April 8, 2024 updated by: Wayne W. Fisher, Ph.D., BCBA-D, LP, Rutgers, The State University of New Jersey
Stimulus Control Refinements of Functional Communication Training
Although treatments for problem behavior, like functional communication training (FCT), can be highly effective in the clinic, changes in the way the FCT is implemented (e.g., when transferring treatment to the home, when teachers implement treatment with poor fidelity) can result in treatment relapse.
The goal of this study is to evaluate whether using treatment signals and gradually introducing materials from natural contexts can help mitigate treatment relapse during context changes and poor treatment-integrity scenarios.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The most common treatment for problem behavior is functional communication training (FCT).
FCT involves teaching children to request what they want, rather than engaging in problem behavior when they don't get their way, and then teach them that they cannot always ask for their way and instead must wait or work appropriately first.
While FCT is effective, problem behavior sometimes comes back after treatment when children encounter treatment challenges, like long periods of not getting their way, when caregivers deliver treatment differently than what they are used to (e.g., caregivers delivering FCT incorrectly), or experiencing treatment in a new place (e.g., the home, the classroom).
The purpose of this research study is to determine whether the experimenters can reduce the chances of children returning to problem behavior during these challenges by teaching them to pay attention to treatment signals (e.g., a red card that indicates treatment is in place) and gradually changing the treatment setting to appear more like the home or classroom.
First, the experimenters will provide each child with their way in a home-like environment containing a couch, rug, etc. Next, within a barren therapy room, the experimenters will conduct two of the following three types of treatments: (1) a treatment with no signals that indicate when their child can and cannot have their way, (2) a treatment with signals, and (3) a treatment with signals plus introduction of items from the natural environment such as rugs and couches.
Then, the experimenters will introduce three common treatment challenges in a row to determine whether treatment signals reduce relapse of problem behavior.
First, the experimenters will introduce the treatments in the home-like environment to see if the child continues to respond appropriately in a setting different than the therapy room.
Second, the experimenters will simulate a transition to the school by having the child experience treatment in a classroom-like environment (e.g., with desks and chalkboards) while the teacher makes the child wait a long period of time to get their way.
This would be similar to when a teacher cannot give the child attention or a preferred item because they are busy with other students.
Third, the experimenters will simulate the teacher implementing treatment differently than the child is used to in the classroom by the teacher delivering preferred activities according to a timed schedule rather than when the child asks.
This simulates the common event of a teacher delivering preferred activities like breaks or recess regardless of the child's behavior.
The goal is to determine how well the treatments perform across each of these common challenges.
Study Type
Interventional
Enrollment (Estimated)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wayne W Fisher, PhD
- Phone Number: 8488008503
- Email: wayne.fisher@rutgers.edu
Study Contact Backup
- Name: Serena Claiborne
- Phone Number: 8488008504
- Email: sclaiborne@childrens-specialized.org
Study Locations
-
-
New Jersey
-
Somerset, New Jersey, United States, 00873
- Recruiting
- Children's Specialized Hospital - Rutgers University Center for Autism Research, Education, and Services
-
Contact:
- Wayne Fisher, PhD
- Phone Number: 848-800-8503
- Email: wayne.fisher@rutgers.edu
-
Contact:
- Serena Claiborne
- Phone Number: 8488008504
- Email: sclaiborne@childrens-specialized.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 17 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Boys and girls from ages 3 to 17
- Destructive behavior that occurs at least 10 times a day despite previous treatment
- Destructive behavior reinforced by social consequences like attention (FCT is not appropriate for automatically reinforced destructive behavior)
- On a stable psychoactive drug regimen for at least 10 half-lives per drug or drug free
- Stable educational plan and placement with no anticipated changes during the child's treatment
Exclusion Criteria:
- Patients who do not meet the inclusion criteria
- Patients currently receiving 15 or more hours per week of treatment for their destructive behavior
- DSM-5 diagnosis of Rett syndrome or other degenerative conditions (e.g., inborn error of metabolism)
- A comorbid health condition or major mental disorder that would interfere with study participation
- Occurrence of SIB during study assessments that presents a risk of serious or permanent harm (e.g., detached retinas) based on our routine clinical-risk assessment
- Patients requiring drug-treatment changes, but the experimenters will invite these patients to participate if they meet inclusion criteria after drug regimen is stable.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mult FCT/Trad FCT
Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules (mult FCT) to evaluate the effects of mult FCT on renewal, super-resurgence, and reinstatement.
|
This intervention emulates a traditional reinforcement schedule-thinning method during FCT in which clinicians program delays to reinforcement without discriminative stimuli (e.g., the child learns that some FCRs result in reinforcement and some do not).
By programming reinforcement approximately every 15 s, the rate of reinforcement will be equivalent to mult FCT.
During Period 1 of this project, trad FCT served as an appropriate control condition to which mult FCT could be compared.
This intervention involves correlating discriminative stimuli (e.g., purple and yellow index cards) with times in which reinforcement for the functional communication response (FCR) is and is not available.
During Period 1 of this project, this procedure resulted in rapid reduction of destructive behavior and mitigated resurgence and renewal when the discriminative stimuli were used as programmed.
|
Experimental: Mult FCT + Stimulus Fading/Trad FCT
Participants assigned to this condition will receive both traditional FCT (trad FCT) and FCT with multiple schedules and stimulus fading (mult FCT + stimulus fading) to evaluate the effects of mult FCT and gradual fading of contextual stimuli on renewal, super-resurgence, and reinstatement.
|
This intervention emulates a traditional reinforcement schedule-thinning method during FCT in which clinicians program delays to reinforcement without discriminative stimuli (e.g., the child learns that some FCRs result in reinforcement and some do not).
By programming reinforcement approximately every 15 s, the rate of reinforcement will be equivalent to mult FCT.
During Period 1 of this project, trad FCT served as an appropriate control condition to which mult FCT could be compared.
This condition is similar to mult FCT except that the experimenters will gradually incorporate natural stimuli (e.g., rugs, tables, lamps) into sessions to approximate target settings that may occasion relapse typically without such gradual stimulus fading.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Destructive Behavior in Renewal Test
Time Frame: Through study completion, an average of 3 weeks.
|
The investigators will measure the rate of destructive behavior following successful treatment when the FCT is implemented in a context not associated with treatment (e.g., the baseline, home-like context).
|
Through study completion, an average of 3 weeks.
|
Rate of Destructive Behavior in Super-Resurgence Test
Time Frame: Through study completion, an average of 3 weeks.
|
The investigators will measure the rate of destructive behavior when FCT is implemented in a context not associated with treatment (e.g., a classroom context) by an implementer who fails to reinforce the communication response.
This would be similar to a busy teacher in a classroom who is unable to attend to the child due to assisting another student.
|
Through study completion, an average of 3 weeks.
|
Rate of Destructive Behavior in Reinstatement Test
Time Frame: Through study completion, an average of 3 weeks.
|
The investigators will measure the rate of destructive behavior when FCT is not implemented as prescribed (i.e., reinforcement is delivered on a time-based schedule, rather than following communication responses).
This would be similar to a teacher who delivers breaks from work based on the school schedule (e.g., switching from math to reading) rather than the child's request for a break during the math period).
|
Through study completion, an average of 3 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Wayne W Fisher, PhD, Rutgers, The State University of New Jersey
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 3, 2021
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
August 1, 2019
First Submitted That Met QC Criteria
August 2, 2019
First Posted (Actual)
August 5, 2019
Study Record Updates
Last Update Posted (Actual)
April 9, 2024
Last Update Submitted That Met QC Criteria
April 8, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro2019001493
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The experimenters plan to make data available to participants, if requested, and submit results for publication.
IPD Sharing Time Frame
The informed consent form shall be available to the caregiver immediately after caregiver signature.
If requested, the study protocol will be sent to the caregiver after the study is complete.
IPD Sharing Access Criteria
Each caregiver of a child enrolled in the study will be eligible to receive the above documents.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aggression
-
University of KonstanzCompletedAppetitive AggressionGermany
-
New York State Psychiatric InstituteCompletedIrritable AggressionUnited States
-
Boston UniversityU.S. Department of JusticeCompletedSexual Aggression | Offensive Aggression | Dating Violence Perpetration and VictimizationUnited States
-
Supernus Pharmaceuticals, Inc.CompletedImpulsive AggressionUnited States
-
Weill Medical College of Cornell UniversityGreen Chimneys Residential Treatment Center, Brewster, NYCompletedChildhood AggressionUnited States
-
University of WashingtonNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Arizona State UniversityCompletedHeavy Drinking | Sexual AggressionUnited States
-
Children's Hospital Medical Center, CincinnatiCompleted
-
Supernus Pharmaceuticals, Inc.CompletedImpulsive Aggression Comorbid With ADHDUnited Kingdom
-
Arizona State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Georgia State UniversityNot yet recruitingAlcohol Drinking | Sexual Behavior | Emotions | Sexual AggressionUnited States
-
Arizona State UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Georgia State UniversityCompletedAlcohol Drinking | Sexual Behavior | Emotions | Sexual AggressionUnited States
Clinical Trials on Trad FCT
-
Matthew J O'Brien, PhD, BCBA-DNational Institute of Mental Health (NIMH); Emory University; University of Houston and other collaboratorsCompletedAutism Spectrum DisorderUnited States
-
Universidad de AlmeriaCompleted
-
Yale UniversityMedela AGCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Wenzhou Medical UniversityCompletedDeep Anterior Lamellar Keratoplasty | Glycerin Cryopreserved Acellular Corneal Tissue | High Risk KeratoplastyChina
-
Bionorica SETerminatedMastodynia | Premenstrual SyndromeGermany
-
Rutgers, The State University of New JerseyAutism SpeaksRecruitingAggression | Problem Behavior | Self-InjuryUnited States
-
Novartis PharmaceuticalsCompletedHereditary HemochromatosisBelgium, France, Russian Federation, Romania, Slovakia, Spain, Switzerland
-
Boehringer IngelheimCompleted
-
Novartis PharmaceuticalsCompletedNon-transfusion-dependent Thalassemia | Transfusion-dependent ThalassemiaEgypt, Turkey, Thailand, Lebanon, Morocco, Saudi Arabia, Vietnam